725 related articles for article (PubMed ID: 25746740)
1. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
2. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
[TBL] [Abstract][Full Text] [Related]
3. Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2012 Nov; 22(21):6632-5. PubMed ID: 23010267
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Pretorius J; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2008 Sep; 16(18):8676-84. PubMed ID: 18723354
[TBL] [Abstract][Full Text] [Related]
5. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
[TBL] [Abstract][Full Text] [Related]
6. Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
Van der Walt MM; Terre'Blanche G; Petzer JP; Petzer A
Eur J Med Chem; 2017 Jan; 125():1193-1199. PubMed ID: 27855360
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC).
Vlok N; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2006 May; 14(10):3512-21. PubMed ID: 16442801
[TBL] [Abstract][Full Text] [Related]
8. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Petzer JP; Petzer A
Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
[TBL] [Abstract][Full Text] [Related]
9. Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B.
Van der Walt MM; Terre'Blanche G; Lourens AC; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2012 Dec; 22(24):7367-70. PubMed ID: 23122857
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Stössel A; Schlenk M; Hinz S; Küppers P; Heer J; Gütschow M; Müller CE
J Med Chem; 2013 Jun; 56(11):4580-96. PubMed ID: 23631427
[TBL] [Abstract][Full Text] [Related]
12. Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
Załuski M; Schabikowski J; Schlenk M; Olejarz-Maciej A; Kubas B; Karcz T; Kuder K; Latacz G; Zygmunt M; Synak D; Hinz S; Müller CE; Kieć-Kononowicz K
Bioorg Med Chem; 2019 Apr; 27(7):1195-1210. PubMed ID: 30808606
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of monoamine oxidase by C5-substituted phthalimide analogues.
Manley-King CI; Bergh JJ; Petzer JP
Bioorg Med Chem; 2011 Aug; 19(16):4829-40. PubMed ID: 21778064
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues.
Mostert S; Mentz W; Petzer A; Bergh JJ; Petzer JP
Bioorg Med Chem; 2012 Dec; 20(24):7040-50. PubMed ID: 23122934
[TBL] [Abstract][Full Text] [Related]
15. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
Legoabe LJ; Petzer A; Petzer JP
Eur J Med Chem; 2012 Mar; 49():343-53. PubMed ID: 22309913
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Prins LH; Petzer JP; Malan SF
Eur J Med Chem; 2010 Oct; 45(10):4458-66. PubMed ID: 20674099
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues.
Petzer A; Grobler P; Bergh JJ; Petzer JP
J Pharm Pharmacol; 2014 May; 66(5):677-87. PubMed ID: 24313346
[TBL] [Abstract][Full Text] [Related]
19. Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase.
Booysen HP; Moraal C; Terre'Blanche G; Petzer A; Bergh JJ; Petzer JP
Bioorg Med Chem; 2011 Dec; 19(24):7507-18. PubMed ID: 22055712
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of monoamine oxidase by phthalide analogues.
Strydom B; Bergh JJ; Petzer JP
Bioorg Med Chem Lett; 2013 Mar; 23(5):1269-73. PubMed ID: 23374869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
